Bilirubin as a potential causal factor in type 2 diabetes risk: A mendelian randomization study

Diabetes

Volumn 64, Issue 4, 2015, Pages 1459-1469

  Abbasi, Ali ^a,b   Deetman, Petronella E ^a   Corpeleijn, Eva ^a   Gansevoort, Ron T ^a   Gans, Rijk O B ^a   Hillege, Hans L ^a   Van Der Harst, Pim ^a,c   Stolk, Ronald P ^a   Navis, Gerjan ^a   Alizadeh, Behrooz Z ^a   Bakker, Stephan J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; GLUCOSE; GLUCURONOSYLTRANSFERASE; INSULIN; ORGANIC ANION TRANSPORTER; SLC22A18 PROTEIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; UNCLASSIFIED DRUG; UGT1A1 ENZYME;

ADULT; AGED; ALLELE; ARTICLE; BILIRUBIN BLOOD LEVEL; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PLEIOTROPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADULT; AGED; ALLELES; BILIRUBIN; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84962023207     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0228     Document Type: Article

References (51)

1. Lin R, Wang Y, Wang Y, et al. Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population. Pharmacogenet Genomics 2009;19: 310-318
2. Cheriyath P, Gorrepati VS, Peters I, et al. High total bilirubin as a protective factor for diabetes mellitus: An analysis of NHANES data from 1999 -2006. J Clin Med Res 2010;2: 201-206
3. Ikeda N, Inoguchi T, Sonoda N, et al. Biliverdin protects against the deterioration of glucose tolerance in db/db mice. Diabetologia 2011;54: 2183-2191
4. Horsfall LJ, Nazareth I, Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation 2012;126: 2556-2564
5. Lin JP, O'Donnell CJ, Schwaiger JP, et al. Association between the UGT1A1∗28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006;114: 1476-1481
6. Jenko-Pražnikar Z, Petelin A, Jurdana M, Žiberna L. Serum bilirubin levels are lower in overweight asymptomatic middle-aged adults: An early indicator of metabolic syndrome? Metabolism 2013;62: 976-985
7. Duann P, Lianos EA. GEC-targeted HO-1 expression reduces proteinuria in glomerular immune injury. Am J Physiol Renal Physiol 2009;297: F629-F638
8. Abraham NG, Asija A, Drummond G, Peterson S. Heme oxygenase -1 gene therapy: Recent advances and therapeutic applications. Curr Gene Ther 2007;7: 89-108
9. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: A major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002;99: 16093-16098
10. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987;235: 1043-1046
11. Alizadeh BZ, Njajou OT, Houwing-Duistermaat JJ, et al. Does bilirubin protect against hemochromatosis gene (HFE) related mortality? Am J Med Genet A 2004;129A: 39-43
12. Iribarren C, Reed DM, Chen R, Yano K, Dwyer JH. Low serum cholesterol and mortality. Which is the cause and which is the effect? Circulation 1995;92: 2396-2403
13. Thanassoulis G, O'Donnell CJ. Mendelian randomization: Nature's randomized trial in the post-genome era. JAMA 2009;301: 2386-2388
14. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27: 1133-1163
15. Buch S, Schafmayer C, Völzke H, et al. Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology 2010;139: 1942-1951
16. Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010; 56: 1535-1543
17. Johnson AD, Kavousi M, Smith AV, et al. Genome-wide association metaanalysis for total serum bilirubin levels. Hum Mol Genet 2009;18: 2700-2710
18. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT; PREVEND Study Group. Albuminuria assessed from first-morningvoid urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008;168: 897-905
19. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT; PREVEND Study Group Prevention of REnal and Vascular ENT Stage Disease. Pharmacy data in epidemiological studies: An easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf 2002;11: 379-384
20. Abbasi A, Corpeleijn E, Meijer E, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 2012;55: 1963-1970
21. Abbasi A, Peelen LM, Corpeleijn E, et al. Prediction models for risk of developing type 2 diabetes: Systematic literature search and independent external validation study. BMJ 2012;345: E5900
22. Verweij N, Mahmud H, Mateo Leach I, et al. Genome-wide association study on plasma levels of midregional-proadrenomedullin and C-terminal-proendothelin-1. Hypertension 2013;61: 602-608
23. Stender S, Frikke-Schmidt R, Nordestgaard BG, Grande P, Tybjaerg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: Three Mendelian randomization studies and a meta-analysis. J Intern Med 2013;273: 59-68
24. Palmer TM, Sterne JA, Harbord RM, et al. Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. Am J Epidemiol 2011;173: 1392-1403
25. Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol 2014; 43: 922-929
26. Li N, van der Sijde MR, Bakker SJ, et al.; LifeLines Cohort Study Group. Pleiotropic effects of lipid genes on plasma glucose, HbA1c, and HOMA-IR levels. Diabetes 2014;63: 3149-3158
27. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013;37: 658-665
28. Morris AP, Voight BF, Teslovich TM, et al.; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012;44: 981-990
29. Dupuis J, Langenberg C, Prokopenko I, et al.; DIAGRAM Consortium; GIANT Consortium; Global BPgen Consortium; Anders Hamsten on behalf of Procardis Consortium; MAGIC Investigators. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42: 105-116
30. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian randomization. Int J Epidemiol 2013;42: 1134-1144
31. Sanna S, Busonero F, Maschio A, et al. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet 2009;18: 2711-2718
32. Van Campenhout A, Van Campenhout C, Lagrou AR, et al. Impact of diabetes mellitus on the relationships between iron-, inflammatory-and oxidative stress status. Diabetes Metab Res Rev 2006;22: 444-454
33. Robertson RP, Harmon JS. Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 2006;41: 177-184
34. Seppen J, Bosma P. Bilirubin, the gold within. Circulation 2012;126: 2547-2549
35. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115: 1111-1119
36. Li N, Frigerio F, Maechler P. The sensitivity of pancreatic beta-cells to mitochondrial injuries triggered by lipotoxicity and oxidative stress. Biochem Soc Trans 2008;36: 930-934
37. Yamagishi S. [Role of advanced glycation end products (AGE) and soluble receptor for AGE (sRAGE) in vascular complications in diabetes]. Nihon Rinsho 2012;70(Suppl. 5): 243-247
38. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999;48: 1-9
39. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000;408: 239-247
40. Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol 2012;3: 55
41. Riphagen IJ, Deetman PE, Bakker SJ, et al. Bilirubin and progression of nephropathy in type 2 diabetes: A post hoc analysis of RENAAL with independent replication in IDNT. Diabetes 2014;63: 2845-2853
42. Fu YY, Kang KJ, Ahn JM, et al. Hyperbilirubinemia reduces the streptozotocininduced pancreatic damage through attenuating the oxidative stress in the Gunn rat. Tohoku J Exp Med 2010;222: 265-273
43. Dong H, Huang H, Yun X, et al. Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation. Endocrinology 2014;155: 818-828
44. Jung CH, Lee MJ, Kang YM, et al. Higher serum bilirubin level as a protective factor for the development of diabetes in healthy Korean men: A 4 year retrospective longitudinal study. Metabolism 2014;63: 87-93
45. Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: New insights into molecular mechanisms and consequences. Gastroenterology 2014;146: 1625-1638
46. Manolio TA, Bailey-Wilson JE, Collins FS. Genes, environment and the value of prospective cohort studies. Nat Rev Genet 2006;7: 812-820
47. Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009;361: 1152-1163
48. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 2011;40: 740-752
49. Maruhashi T, Soga J, Fujimura N, et al. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation 2012;126: 598-603
50. Pfister R, Sharp S, Luben R, et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: Evidence of causal association from population studies. PLoS Med 2011;8: E1001112
51. Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Extreme bilirubin levels as a causal risk factor for symptomatic gallstone disease. JAMA Intern Med 2013;173: 1222-1228